A detailed history of Shell Asset Management CO transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 9,474 shares of FLGT stock, worth $185,216. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,474
Previous 9,809 3.42%
Holding current value
$185,216
Previous $192,000 7.29%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$19.6 - $25.06 $6,566 - $8,395
-335 Reduced 3.42%
9,474 $206,000
Q1 2024

Jul 31, 2024

SELL
$21.55 - $29.29 $13,296 - $18,071
-617 Reduced 5.92%
9,809 $192,000
Q1 2024

May 14, 2024

SELL
$21.55 - $29.29 $7,995 - $10,866
-371 Reduced 3.44%
10,426 $226,000
Q4 2023

Feb 14, 2024

SELL
$23.64 - $30.27 $76,475 - $97,923
-3,235 Reduced 23.05%
10,797 $312,000
Q3 2023

Nov 08, 2023

SELL
$26.74 - $40.81 $6,524 - $9,957
-244 Reduced 1.71%
14,032 $375,000
Q2 2023

Jul 28, 2023

SELL
$28.52 - $40.7 $65,310 - $93,203
-2,290 Reduced 13.82%
14,276 $529,000
Q1 2023

May 15, 2023

BUY
$29.39 - $36.27 $376,632 - $464,800
12,815 Added 341.64%
16,566 $517,000
Q4 2022

Feb 07, 2023

SELL
$29.23 - $40.28 $22,302 - $30,733
-763 Reduced 16.9%
3,751 $112,000
Q3 2022

Nov 14, 2022

BUY
$37.92 - $63.74 $36,175 - $60,807
954 Added 26.8%
4,514 $172,000
Q2 2022

Aug 09, 2022

BUY
$47.98 - $62.75 $54,841 - $71,723
1,143 Added 47.29%
3,560 $194,000
Q1 2022

May 04, 2022

SELL
$49.85 - $96.11 $17,796 - $34,311
-357 Reduced 12.87%
2,417 $151,000
Q4 2021

Feb 09, 2022

BUY
$77.3 - $105.0 $1,004 - $1,365
13 Added 0.47%
2,774 $279,000
Q3 2021

Nov 04, 2021

SELL
$74.87 - $110.87 $8,984 - $13,304
-120 Reduced 4.17%
2,761 $248,000
Q2 2021

Aug 12, 2021

BUY
$66.8 - $100.45 $192,450 - $289,396
2,881 New
2,881 $266,000

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $592M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.